Stock comparison
BlackRock Technology and Private Equity Term
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BTX
BlackRock Technology and Private Equity Term
Market cap
$1.04B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BTX | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 79B | HALO |
| Benjamin Graham | 46D | 83A | HALO |
| Philip Fisher | 62C | 65B | HALO |
| Peter Lynch | 56C | 53D | BTX |
| Joel Greenblatt | 44D | 40D | BTX |
| Charlie Munger | 41D | 80C | HALO |
| Terry Smith | 45D | 84A | HALO |
Side-by-side metrics
| Metric | BTX | HALO |
|---|---|---|
| Market cap | $1.04B | $8.1B |
| P/E (TTM) | 50.0x | 24.0x |
| EV/EBIT | 27.0x | 10.2x |
| ROIC (TTM) | 3.85% | 23.65% |
| Gross margin | 100.0% | 81.24% |
| Net margin | 87.75% | 23.13% |
| Revenue CAGR 5y | - | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | - | 1.0x |
| Dividend yield | 9.29% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BTX leads on
- Debt / Equity-vs 1.0x+100%
- Dividend yield9.29%vs 0.0%+100%
- Net margin87.75%vs 23.13%+74%
- Gross margin100.0%vs 81.24%+19%
HALO leads on
- Market cap$8.1Bvs $1.04B+87%
- ROIC (TTM)23.65%vs 3.85%+84%
- EV/EBIT10.2xvs 27.0x+62%
- P/E (TTM)24.0xvs 50.0x+52%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.